It is key to note that our study is the first to validate BreastAnalyser and to address Cx43 expression in the context of breast cancer samples scored according to the pioneering diagnostic test Oncotype DX, putting forward the possibility of Cx43 as a complementary prognostic marker to take into consideration. This evidence concerns the gene GJA1 and breast carcinoma.